Dr David Robert Grimes looks at the eye health issues that are making the news.
NHS to save millions on AMD treatment
A landmark ruling promises to substantially reduce the cost of treating wet age-related macular degeneration (AMD) – and has significant implications for future drug policy. Bayer and Novartis had attempted to stop clinical commissioning groups (CCGs) from prescribing Avastin – a widely used and cheaper treatment, but unlicensed for AMD.
In September, the High Court ruled against the drug giants.
Sign in to continue
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
In this article we will outline the importance of developing standards for affordable and accessible low-vision service delivery that can be applied globally and that are relevant to both the developed and developing world.
This narrative review summarises emerging interventions that may be mentioned in the popular and professional press, and may be on our menu of treatment options to discuss with patients in the near future.
